Company Overview and News
2018-07-30 seekingalpha - 6
The first half of 2018 was marked by plenty of news and significant volatility from BOTB Club stocks.
CRC LGCYP LGCYO LNGG CHKVP CRK CHKVZ SQTI EXXIQ KMI RXNRP EXIXQ SNZYP KMR AST CVB SN NBL TALO SRCI EEXXQ RRS JONE EXXI RGRLF RRC DNR CHK SGY TTEN LINE ECR UPL REN PVA EPE RRL SCAZP CHKDH XCOOQ ACTPF CHKDG VNGE AREX CHKDJ CHKDP REXXQ JNEEP XCOO LINEQ CKRGZ EVEP PVAYQ CHKWZ XCO RGRYY REXX CHK.WI PVAC LGCY UPLMQ BRY KMRFZ
Investors in Ultra Petroleum Corp. (UPL - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 17, 2018 $2.50 Call had some of the highest implied volatility of all equity options today.
UPL GTT KRYS UPLMQ
Avis Budget Group, Inc. (CAR - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because CAR recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
GOOS UPL ABX AXTA UPLMQ CAR ABX
2018-07-02 zacks - 1
Investors certainly have to be happy with Ultra Petroleum Corp. (UPL - Free Report) and its short-term performance. After all, the stock has jumped by 39.8% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for UPL?
2018-06-11 zacks - 1
It has been about a month since the last earnings report for Ultra Petroleum Corp. (UPL - Free Report) . Shares have lost about 2.5% in that time frame.
HAWLN UPL HSC HAWLM HAWLL HAWLI UPLMQ HAWEL HAWEN HAWEM
On May 8, President Trump announced that the United States is exiting the Iran nuclear pact. Trump now plans to impose new sanctions on Iran. On May 21, US Secretary of State Mike Pompeo announced a list of demands for Iran. The demands are a prerequisite for any new agreement. He highlighted that all uranium enrichment activity must stop. Pompeo also said that all support activities for militants in the Middle East should stop.
UPL CVI UPLMQ
19h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
19h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
21h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to UPL / Ultra Petroleum Corp. on message board site Silicon Investor.
as of ET